We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Signet Announces Availability of two Monoclonal Antibodies, L1 and PTEN
Product News

Signet Announces Availability of two Monoclonal Antibodies, L1 and PTEN

Signet Announces Availability of two Monoclonal Antibodies, L1 and PTEN
Product News

Signet Announces Availability of two Monoclonal Antibodies, L1 and PTEN


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Signet Announces Availability of two Monoclonal Antibodies, L1 and PTEN "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Signet Laboratories, Inc. has announced the availability of two monoclonal antibodies L1 clone 14.10 and PTEN clone 6H2.1

The mouse monoclonal anti-L1 clone 14.10 recognizes the L1 protein (CD171), a transmembrane protein that belongs to the immunoglobulin supergene family.

Data indicate that L1 may be overexpressed in a variety of carcinomas. Studies have implicated L1 as a marker of unfavorable prognosis in a variety of malignancies.

Clone 6H2.1 recognizes PTEN (phosphatase and tensin homolog), a tumor suppressor protein that is encoded by a gene located on chromosome 10. PTEN mutations have been observed in a wide range of cancers.

The addition of L1 and PTEN complements Signet's current product offerings for cancer research. Signet's product portfolio includes markers such as D2- 40, Cyclin D1, Cyclin E, HE4 and Hepsin.

Advertisement